Literature DB >> 17673880

Should hypertension guidelines be changed for hypertensive patients with the metabolic syndrome?

Julian Segura1, Jose Ramon Banegas, Jose Antonio García-Donaire, Fernando Rodríguez-Artalejo, Juan Jose de la Cruz, Manuel Praga, Luis Miguel Ruilope.   

Abstract

The authors analyzed the impact of present guidelines for hypertension management on cardiovascular (CV) risk factors in hypertensive patients with and without the metabolic syndrome (MS). Results in 549 nondiabetic hypertensive patients with a mean follow-up of 3.8+/-1.2 years on usual recommended care were reviewed. At baseline, 231 (42.1%) patients had MS and, per the definition, showed significantly higher values of traditional CV risk factors than non-MS patients. At the end of follow-up, blood pressure levels were similar in both groups; the lipid profile tended to improve in MS patients. Eighteen MS patients (7.8%) and 7 non-MS patients (2.2%) developed diabetes (P<.001). Prevalence of microalbuminuria was reduced in both groups, but it remained significantly higher in MS patients. Usual care of hypertensive patients achieved similar blood pressure and low-density lipoprotein cholesterol goals, both in MS and non-MS patients. Global CV risk, however, remained higher in MS patients, as suggested by a 3-fold higher incidence of new-onset diabetes (absolute increase of 5.6%) and a 2-fold increase in microalbuminuria.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17673880      PMCID: PMC8110164          DOI: 10.1111/j.1524-6175.2007.06522.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  22 in total

Review 1.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.

Authors:  Scott M Grundy; James I Cleeman; Stephen R Daniels; Karen A Donato; Robert H Eckel; Barry A Franklin; David J Gordon; Ronald M Krauss; Peter J Savage; Sidney C Smith; John A Spertus; Fernando Costa
Journal:  Circulation       Date:  2005-09-12       Impact factor: 29.690

Review 2.  New-onset diabetes and antihypertensive drugs.

Authors:  Giuseppe Mancia; Guido Grassi; Alberto Zanchetti
Journal:  J Hypertens       Date:  2006-01       Impact factor: 4.844

Review 3.  Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies.

Authors:  Apoor S Gami; Brandi J Witt; Daniel E Howard; Patricia J Erwin; Lisa A Gami; Virend K Somers; Victor M Montori
Journal:  J Am Coll Cardiol       Date:  2007-01-12       Impact factor: 24.094

4.  The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes.

Authors:  Carlos Lorenzo; Ken Williams; Kelly J Hunt; Steven M Haffner
Journal:  Diabetes Care       Date:  2007-01       Impact factor: 19.112

Review 5.  Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome.

Authors:  William Bestermann; Mark C Houston; Jan Basile; Brent Egan; Carlos M Ferrario; Dan Lackland; Ralph G Hawkins; James Reed; Philip Rogers; Daniel Wise; Michael A Moore
Journal:  Am J Med Sci       Date:  2005-06       Impact factor: 2.378

Review 6.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Richard Kahn; John Buse; Ele Ferrannini; Michael Stern
Journal:  Diabetes Care       Date:  2005-09       Impact factor: 19.112

Review 7.  Do we need to target 'prediabetic' hypertensive patients?

Authors:  Julián Segura; Carlos Campo; Luis M Ruilope; José L Rodicio
Journal:  J Hypertens       Date:  2005-12       Impact factor: 4.844

8.  Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?

Authors: 
Journal:  Diabetes Care       Date:  2003-03       Impact factor: 19.112

Review 9.  Abdominal obesity and metabolic syndrome.

Authors:  Jean-Pierre Després; Isabelle Lemieux
Journal:  Nature       Date:  2006-12-14       Impact factor: 49.962

10.  2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension.

Authors: 
Journal:  J Hypertens       Date:  2003-06       Impact factor: 4.844

View more
  4 in total

1.  Modelling the costs of care of hypertension in patients with metabolic syndrome and its consequences, in Germany, Spain and Italy.

Authors:  Eberhard Wille; Jürgen Scholze; Eduardo Alegria; Claudio Ferri; Sue Langham; Warren Stevens; David Jeffries; Kerstin Uhl-Hochgraeber
Journal:  Eur J Health Econ       Date:  2010-04-20

2.  Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in Germany, Spain and Italy; a prevalence-based model.

Authors:  Jürgen Scholze; Eduardo Alegria; Claudio Ferri; Sue Langham; Warren Stevens; David Jeffries; Kerstin Uhl-Hochgraeber
Journal:  BMC Public Health       Date:  2010-09-02       Impact factor: 3.295

Review 3.  Impact of treating the metabolic syndrome on chronic kidney disease.

Authors:  Varun Agrawal; Aashish Shah; Casey Rice; Barry A Franklin; Peter A McCullough
Journal:  Nat Rev Nephrol       Date:  2009-07-28       Impact factor: 28.314

Review 4.  Treatment of prehypertension in diabetes and metabolic syndrome: what are the pros?

Authors:  Julian Segura; Luis M Ruilope
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.